EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mycobacterium indicus pranii (MIP) Vaccine: A Narrative Review of Current Evidence on Selected Clinical Conditions, Challenges, and Future Directions

Sanidhya Bhargava, Parteek Walia, Sachin Gupta, Neena Khanna

Vaccines · 13.11.2026 · 14 (11) · 977

DOI: 10.3390/vaccines14110977 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 13.11.2026. Verfasst von Sanidhya Bhargava und 3 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycobacterium indicus pranii (MIP), formerly designated Mycobacterium w (Mw), is an inactivated, heat-killed, non-pathogenic Mycobacterium with well-characterized immunomodulatory properties, originally developed in India. Initially introduced as an adjunct to multidrug therapy (MDT) for leprosy, MIP has since demonstrated significant therapeutic and prophylactic potential across a broad spectrum of infectious and non-infectious conditions, including tuberculosis (TB), COVID-19, leishmaniasis, cutaneous warts, sepsis, and select malignancies. Clinical and observational studies have reported improved clinical outcomes, accelerated bacillary clearance, and sustained immunological benefits across multiple disease contexts. Despite these promising findings, several barriers impede the broader integration of MIP into public health programmes. These include the absence of large-scale, adequately powered efficacy trials; insufficient immunological characterization; limited operational and socio-behavioural feasibility data; poor awareness within the healthcare system; and challenges with long-term patient follow-up, particularly in mobile or migrant populations. Future research directions underscore MIP’s potential as a prophylactic and therapeutic agent against COVID-19, an adjunctive therapy for drug-resistant TB, and an immunotherapeutic candidate in oncology. Addressing existing research gaps through rigorously designed clinical, immunological, and implementation studies will be essential to realizing MIP’s full potential in global health.

Zitieren

APA

Bhargava, S., Walia, P., Gupta, S., & Khanna, N. (2026). Mycobacterium indicus pranii (MIP) Vaccine: A Narrative Review of Current Evidence on Selected Clinical Conditions, Challenges, and Future Directions. Vaccines, 14(11), 977. https://doi.org/10.3390/vaccines14110977

Vancouver

Bhargava S, Walia P, Gupta S, Khanna N. Mycobacterium indicus pranii (MIP) Vaccine: A Narrative Review of Current Evidence on Selected Clinical Conditions, Challenges, and Future Directions. Vaccines. 2026;14(11):977. doi:10.3390/vaccines14110977

BibTeX
@article{Bhargava2026,
  author = {Bhargava, Sanidhya and Walia, Parteek and Gupta, Sachin and Khanna, Neena},
  title = {Mycobacterium indicus pranii (MIP) Vaccine: A Narrative Review of Current Evidence on Selected Clinical Conditions, Challenges, and Future Directions},
  journal = {Vaccines},
  year = {2026},
  volume = {14},
  number = {11},
  pages = {977},
  doi = {10.3390/vaccines14110977}
}
Kostenlos starten →